Pfizer recently announced that its trials in children 2 to 5 years old produced a weaker than expected antibody response and that it would hold off requesting authorization from the Food and Drug Administration. This news creates opportunities – and additional challenges – for off-label use of Covid-19 vaccines in children,

In a new essay in the Hastings Center Report, we argue it is not. Yet the practice is prohibited.

Children have suffered both physical and mental illness during the pandemic. Nearly 200 children in the United States have died. Acute mental health crises increased during the pandemic. Getting children immunized is the best way to get back to normal. We suggest an option that would permit children under 5 to be vaccinated without waiting until traditional prospective randomized trials can be completed.